BRWM
ACAD icon

B. Riley Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

B. Riley Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100
Closed -$3K – 1001
2015
Q1 		$3K Hold
100
– – ﹤0.01% 915
2014
Q4 		$3K Sell
100
-200
-67% -$5.67K ﹤0.01% 897
2014
Q3 		$7K Buy
+300
New +$7.02K 0.01% 846

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

B. Riley Wealth Management's ACAD Position: Q2 2015 in Review

B. Riley Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2015, closing a stake of 100 shares — an estimated $3K sold.

B. Riley Wealth Management first reported a position in ACAD in Q3 2014 and held it in 3 quarters. The position peaked at $7K in Q3 2014. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

  • B. Riley Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • B. Riley Wealth Management sold 100 Acadia Pharmaceuticals shares in Q2 2015, an estimated $3K.
  • B. Riley Wealth Management first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • B. Riley Wealth Management's Acadia Pharmaceuticals position peaked at $7K in Q3 2014.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on B. Riley Wealth Management's 13F filing for Q2 2015, filed 14 Jul 2015.